Current status and perspectives in immunotherapy for metastatic melanoma

Riccardo Marconcini, Francesco Spagnolo, Luigia Stefania Stucci, Simone Ribero, Elena Marra, Francesco D. de Rosa, Virginia Picasso, Lorenza D. di Guardo, Carolina Cimminiello, Stefano Cavalieri, Laura Orgiano, Enrica Tanda, Laura Spano, Alfredo Falcone, Paola Queirolo, Giuseppe Palmieri, Ignazio Stanganelli, Mario Mandalà, Pietro Quaglino, Gerardo BottiCorrado Caracò, Vanna Chiarion Sileni, Anna Maria di Giacomo

Research output: Contribution to journalArticlepeer-review


© Marconcini et al. Metastatic melanoma was the first malignancy in which immune checkpoint inhibitors demonstrated their successful efficacy. Currently, the knowledge on the interaction between the immune system and malignant disease is steadily increasing and new drugs and therapeutic strategies are overlooking in the clinical scenario. To provide a comprehensive overview of immune modulating drugs currently available in the treatment of melanoma as well as to discuss of possible future strategies in the metastatic melanoma setting, the present review aims at analyzing controversial aspects about the optimal immunomodulating treatment sequences, the search for biomarkers of efficacy of immunocheckpoint inhibitors, and innovative combinations of drugs currently under investigation.
Original languageEnglish
Pages (from-to)12452-12470
Number of pages19
Issue number15
Publication statusPublished - Jan 1 2018


  • Immunotherapy
  • Ipilimumab
  • Melanoma
  • Nivolumab
  • Pembrolizumab


Dive into the research topics of 'Current status and perspectives in immunotherapy for metastatic melanoma'. Together they form a unique fingerprint.

Cite this